Understanding the genomics involved in Parkinson’s disease development

1. Understanding the genomics involved in Parkinson’s disease development Over 4 million people worldwide suffer from Parkinson's disease, a degenerative illness of the neurological system. It is brought on by the death of the brain cells that produce dopamine. The substance the brain releases to cause movement in the body is called dopamine. genetics' function Only 15% of Parkinson's cases are genetically based. It's interesting to note that more than 15 genes have already been connected to Parkinson's. 1 Six of the genes are also involved in the pathophysiology of the disease. Parkinson's disease is an autosomal dominant type linked to

2. the SNCA and LRRK2 genes. The rationale is that a mutation in the gene's single copy is sufficient to produce the disease. Here, the cause can be a gene that has undergone a mutation from one of his parents or an entirely new mutation. The mutation is present in both copies of the PRKN, PINK1, DJ-1, and ATP13A2 genes, resulting in the autosomal recessive form of Parkinson's disease. Function of Ethnicity Most of the time, the clinical examination of white patient populations has contributed much to our understanding of the chronic disease. Although population-level genetics and molecular biology have advanced, research on other ethnic groups, such as Asians, has not kept pace, which has led to lasting health disparities. This is so because most research is conducted on white participants in the USA and Europe. Therefore, there are gaps in the research on Parkinson's disease. According to various research, death rates were influenced by ethnic background. For instance, Black patients died more frequently than White patients. However, compared to White patients, the death rate was lower among Hispanic and some Asian patients. However, because all this research was conducted among European and American citizens, patients in India may not be able to use the findings. According to research done in India, the condition was less common. This was partly because India lacked most of the genetic abnormalities found to cause Parkinson's disease in other nations. However, the overwhelming number of Parkinson's patients discovered in India, both in the old age group and those under the age of 40, suggested that variables other than ethnicity may play a role in the condition. Some pharmaceutical companies have taken on the responsibility of conducting clinical trials for the newest new medications in India, safinamide and apomorphine pump therapy, to undertake further research on the therapeutic elements of the illness. 2 In addition, specialised gene-based therapies that target particular cell molecules are being tested to improve outcomes for Parkinson's patients. A good example is a global study that the Michael J. Fox Foundation wants to do to understand the genetics of Parkinson's disease better. This represents a significant advancement considering that a cure has not yet been discovered despite this age-related condition having effective treatment choices like pills, injections, pump therapy, and surgeries. TO KNOW MORE, CLICK BELOW HERE https://neuria.app/